~28 spots leftby Apr 2026

SOLTIVE Laser vs Ho:YAG Laser for Kidney Stones

(Soltive Stone Trial)

Recruiting in Palo Alto (17 mi)
WM
Overseen byWilson Molina, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: University of Kansas Medical Center
No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial compares the new SOLTIVE Thulium laser to the traditional Holmium laser for treating kidney stones. The new laser aims to break down stones more efficiently and with less damage to surrounding tissues, potentially improving patient outcomes and reducing costs. The Thulium fibre laser (TFL) has recently been introduced as a new technology and may challenge the Holmium:YAG (Ho:YAG) laser as the preferred option due to its favorable properties.

Research Team

WM

Wilson Molina, MD

Principal Investigator

University of Kansas Medical Center

Eligibility Criteria

This trial is for adults over 18 with a single kidney stone smaller than 2cm who choose to have it removed using ureteroscopy with laser lithotripsy and extraction. It's not for those with stones larger than 2cm, multiple or bilateral stones, or patients preferring natural stone passage.

Inclusion Criteria

I am choosing to have a specific procedure to remove kidney stones using lasers and a basket.
I have been diagnosed with a kidney stone smaller than 2.0 cm.
I am 18 years old or older.

Exclusion Criteria

I want to keep participating in the clinical trial.
I have kidney stones larger than 2 centimeters.
I have more than one kidney stone or stones in both kidneys.

Treatment Details

Interventions

  • Ho:YAG Laser (Holmium Laser)
  • Percutaneous nephrolithotomy (Procedure)
  • SOLTIVE Thulium Fiber Laser (Thulium Laser)
Trial OverviewThe study compares two types of lasers used in kidney stone treatment: the new SOLTIVE Thulium Fiber Laser versus the traditional Ho:YAG Laser. The goal is to see which one offers better surgery outcomes and physician satisfaction.
Participant Groups
2Treatment groups
Active Control
Group I: Ho:YAG LaserActive Control1 Intervention
Ho:YAG Laser group (laser B)
Group II: SOLTIVE Thulium Fiber LaserActive Control1 Intervention
SOLTIVE Thulium Fiber Laser group (laser A)

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Kansas Medical Center

Lead Sponsor

Trials
527
Recruited
181,000+
Dr. Steve Stites profile image

Dr. Steve Stites

University of Kansas Medical Center

Chief Executive Officer

MD from University of Kansas School of Medicine

Dr. Matthias Salathe profile image

Dr. Matthias Salathe

University of Kansas Medical Center

Chief Medical Officer

MD from University of Kansas School of Medicine